DBVT
USDDBV Technologies S.A. American Depositary Shares
Prix en Temps Réel
Graphique des Prix
Métriques Clés
Métriques de Marché
Ouverture
$14.050
Haut
$15.010
Bas
$14.050
Volume
0.07M
Fondamentaux de l'Entreprise
Capitalisation Boursière
521.2M
Industrie
Biotechnologie
Pays
France
Statistiques de Trading
Volume Moyen
0.10M
Bourse
NCM
Devise
USD
Intervalle sur 52 Semaines
Actualités Connexes
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced the
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (TRQX:DBVp), (the "Company" or "DBV"), a clinical-stage biopharmaceutical
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting
Châtillon, France, October 30, 2025 DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced upcoming
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
Châtillon, France, October 29, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (TRQX:DBVp) (the "Company"), a clinical-stage
HC Wainwright & Co. Maintains Buy on DBV Technologies, Raises Price Target to $20
HC Wainwright & Co. analyst Andrew S. Fein maintains DBV Technologies with a Buy and raises the price target from $16 to $20.
Actions Connexes
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.